In summary, nationwide CrAg screening in patients with advanced HIV disease with a CD4 count of 101–200 cells/μL in Botswana is estimated to have a modest impact (48 deaths avoided annually) for a modest additional cost to the overall HIV/AIDS care and treatment program ($116,000), with a relatively low cost per DALY saved ($114 base case). The gene discussed is CD4; the disease is AIDS.